Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults

AIDS

Volumn 24, Issue 11, 2010, Pages 1727-1731

  Samaras, Katherine ^a   Richardson, Robyn ^b   Carr, Andrew ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

cholesterol; postprandial; protease inhibitor; raltegravir; ritonavir

Indexed keywords

CARBOHYDRATE; FAT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALTEGRAVIR; RITONAVIR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; FATIGUE; FEMALE; FOOD INTAKE; HUMAN; LOW DRUG DOSE; MALE; NAUSEA; OUTCOME ASSESSMENT; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CHOLESTEROL, LDL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HIV SERONEGATIVITY; HUMANS; LIPID METABOLISM; LIPIDS; MALE; POSTPRANDIAL PERIOD; PYRROLIDINONES; RITONAVIR;

EID: 77954332514     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833ac7be     Document Type: Article

References (16)

1. DAD Study Group, Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drug and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
2. Phillips A, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman W, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008; 13:177-187.
3. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318-330.
4. Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med 2005; 6:421-425.
5. Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D, 089 Study Group. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antire-troviral therapy regimens in antiretroviral-naive patients. J Acquir Immun Defic Syndr 2008; 47:161-167.
6. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al., Protocol 004 Part II Study Team. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immun Defic Syndr 2009; 52:350-356.
7. Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villaneuva J, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK-1 and 2): two multicenter, double-blind, randomised controlled trials. Lancet 2010; 375:396-407.
8. Nordestgarrd BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298:299-308.
9. Stein JH, Michelle A, Merwood MA, Jennifer B, Bellehumeur JB, McBride PE, et al. Postprandial lipoprotein changes in patients taking antiretroviral therapy for HIV infection. Arterioscler Thromb Vasc Biol 2005; 25:399-405.
10. Coll B, van Wijk JP, Parra S, Castro Cabezas M, Hoepelman IM, Alonso-VillaverdeC, et al. Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy. Eur J Pharmacol 2006; 544:104-110.
11. Sekhar RV, Jahoor F, Pownall HJ, Rehman K, Gaubatz J, Iyer D, et al. Severely dysregulated disposal of postprandial triacylgly-cerols exacerbates hypertriacylglycerolemia in HIV lipodystro-phy syndrome. Am J Clin Nutr 2005; 81:1405-1410.
12. Thomas-Geevarghese A, Raghavan S, Minolfo R, Holleran S, Ramakrishnan R, Ormsby B, et al. Postprandial response to a physiologic caloric load in HIV-positive patients receiving protease inhibitor-based or nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Am J Clin Nutr 2005; 82:146-154.
13. Kelly RP, Hayward C, Avolio A, O?Rourke MF. Noninvasive determination of age-related changes in the human arterial pulse. Circulation 1989; 80:1652-1659.
14. Greenfield JR, Samaras K, Hayward CS, Chisholm DJ, Campbell LV. Beneficial postprandial effect of a small amount of alcohol on diabetes and cardiovascular risk factors: modification by insulin resistance. J Clin Endocrinol Metab 2005; 90:661-672.
15. Law MG, Friis-Møller N, El-Sadr WM, Weber R, Reiss P, D?Arminio Monforte A, et al., D:A:D Study Group. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D study. HIV Med 2006; 7:218-230.
16. Liang JS, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, Ginsberg HN, et al. HIV protease inhibitors protect apolipo-protein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001; 7:1327-1331.